TickerTalks
Browse all tickers →
TickerTalks›$CVS
CVCVS

CVS Health Corp.

$CVS·$122B·Medical - Healthcare Plans·Healthcare
$97.16+2.3%YTD+31.7%1Y+44.1%
Mentions · last 7 days
2026-08-06: 38 posts2026-08-07: 14 posts2026-08-08: 7 posts2026-08-09: 6 posts2026-08-10: 24 posts2026-08-11: 17 posts2026-08-12: 26 posts135-21%
Price updated 1h ago·X counts updated 2d ago
CVCVS
$CVSCVS Health Corp.
$97.16+2.28%135 posts-21%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $CVS, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Comeback attemptCooling offAI verdict · as of 2026-08-13

Catching its breath after a run — could pick back up or fade from here.

CVS blew through Q2 EPS estimates but the -10% premarket says Caremark 2027 caution is the entire trade.

CVS Health is the integrated pharmacy-retail-plus-health-insurance conglomerate (CVS Retail, Aetna, Caremark PBM). The stock is up 45% over 12 months but the Q2 print was whipsaw — a huge double-beat that got hit 10% premarket on cautious Caremark 2027 commentary.

  • The Q2 print itself is spectacular: adjusted EPS $2.58 vs $1.87 estimate (+38% beat), revenue $106B up 7.3% YoY, and full-year EPS guide raised to $7.90-$8.10 — this is a business genuinely converting operating discipline into printed results.
  • The commercial optionality is real: the LLY Zepbound and Foundayo partnership through the CVS app is a genuine strategic move to capture GLP-1 patient flows, the Healthcare Providers ETF is near ATHs, and the medical benefit ratio improved 250 bps — these are the kind of leading indicators that support a re-rate.
  • The specific breaking point is Caremark 2027: management provided cautious commentary about Caremark PBM membership declines next year, which is exactly the segment that generates the most FCF — that's what triggered the 10% premarket drop and what the skeptics are anchoring on when they dismiss the print as 'juiced.'

The November 4 Q3 print is the reality check — a reaffirmed FY26 EPS guide plus a specific Caremark 2027 membership stabilization commentary is what breaks the cooling upward toward $110. A further Caremark 2027 guide reduction, a specific major-account loss disclosure, or a fresh medical-cost-ratio deterioration is what would take a name at 66% of 52w range back below $85.

Agrees with X sentimentThe whipsawed X tone is right — the Q2 double-beat (EPS $2.58 vs $1.87, revenue +7.3%, FY26 EPS raised to $7.90-$8.10, MBR improving 250bps, LLY Zepbound/Foundayo partnership, Healthcare Providers ETF near ATH) is real, and the -10% premarket on cautious Caremark 2027 commentary is real too. Both camps point at printed data.

What to watch: November 4 Q3 print — a reaffirmed FY26 EPS guide plus Caremark 2027 membership stabilization commentary breaks the cooling upward toward $110; a further Caremark 2027 guide reduction, a major-account loss disclosure, or a fresh medical-cost-ratio deterioration takes it back below $85.

On the calendar: 2026-11-04 — Q3 earnings

float missingbeta missing

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Mixed sentiment⚠23 posts analyzed · as of 2026-08-12 · top-engagement diverged

Sentiment is whipsawed around CVS Health's Q2 double-beat with adjusted EPS of two-fifty-eight against one-eighty-five estimates, revenue up seven-point-three percent and full-year EPS guide raised to seven-ninety to eight-ten, contrasted against a ten-percent premarket collapse on cautious commentary about Caremark membership declines next year. Bulls note the medical benefit ratio improving two-fifty basis points, the LLY Zepbound and Foundayo partnership through the CVS app, and Healthcare Providers ETF near all-time highs. Skeptics dismiss the print as juiced.

Read the AI verdict + X sentiment for $CVS

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Integrated healthcare company operating pharmacies, pharmacy benefit management, health insurance, and MinuteClinic locations across the U.S.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Healthcare Plans sits in its cycle right now — and what that implies for $CVS.

Medical - Healthcare Plans · Healthcare

No material change from last week — Oscar Health's AI-driven clinical platform is gaining member growth while the UNH Medicaid fraud litigation adds regulatory risk to legacy insurers.

What this means for $CVS

Partial — Integrated healthcare company operating pharmacies, pharmacy benefit management, health insurance, and MinuteClinic locations across the U.S; partial earnings exposure to medical - healthcare plans demand dynamics through its product portfolio.

Top industry ETF

$IHFiShares U.S. Healthcare Providers ETF
+17.6%YTD
+29.1%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
44.1How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
2.9%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
1.5%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
5.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.3Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
3.9%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
13.9%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
1.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 5, 2026$2.58$1.87+38.0%
Q1 2026May 6, 2026$2.57$2.21+16.3%
Q4 2025Feb 10, 2026$1.09$1.00+9.0%
Q3 2025Oct 29, 2025$1.60$1.37+16.8%
Next earningsWed, Nov 4·consensus EPS $1.65

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$100.4B+6.2%15.6%4.7%$2.31$3.4B
Q4 FY25$105.7B+8.2%12.8%2.0%$2.32$2.6B
Q3 FY25$102.9B+7.8%13.4%-3.1%$-3.13$98.0M
Q2 FY25$98.9B+8.4%13.7%2.4%$0.81$1.3B

Forward consensus

5-year forecast · up to 18 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$409.0B$405.4B – $414.9B$7.45$7.34 – $7.6418
FY27$426.3B$416.8B – $440.2B$8.44$8.25 – $8.8018
FY28$449.0B$415.8B – $472.6B$9.69$9.03 – $10.1516
FY29$477.4B$464.8B – $495.9B$10.95$10.57 – $11.5015
FY30$498.7B$485.6B – $518.0B$12.20$11.78 – $12.8115

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.9×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.66%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-7.2%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+11.1%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMega float · 1.3B shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.5% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.605-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellMay 21Larry RobbinsDirector748.5K sh$56.7MSellMay 20Larry RobbinsDirector1.0M sh$95.5MSellMay 19Larry RobbinsDirector2.0M sh$187.3MSellMay 8Tilak MandadiEVP, Chief Exp & Tech Officer69.6K sh$6.2M
+ 34 other (22 awards · 10 inkinds · 2 returns) in window

See when $CVS insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

S-3ASRAuto-shelf registrationMay 22S-3ASR
AI summary

CVS Health Corporation filed an automatic shelf registration statement (S-3ASR) on May 22, 2026, enabling the company to offer and sell unspecified amounts of various securities on a delayed or continuous basis. As a large accelerated filer, CVS is eligible for this expedited registration process that becomes effective immediately upon filing without SEC staff review. The registration provides financial flexibility to access capital markets efficiently for potential debt, equity, or hybrid securities offerings. No specific offering terms, size, or timing are determined at the time of filing.

8-KOfficer or director changeMay 188-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary

CVS Health held its 2026 Annual Meeting on May 14, 2026, at which stockholders approved the new 2026 Incentive Compensation Plan (ICP) to replace the expiring 2017 ICP, enabling ongoing equity- and cash-based compensation awards for employees and executives. The meeting also included director elections and other routine corporate matters, with vote tallies included in the full filing. Item 5.02 discloses an officer or director change in connection with the annual meeting. The new 2026 ICP is necessary for CVS to continue making equity grants in the ordinary course of business.

3New insider — initial holdingsMar 193
8-KOfficer or director changeMar 198-K — Item 5.02: Officer or director change
+ 13 other (2 13Fs · 2 10-Qs · 2 earnings 8-Ks · 2 13Gs) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

New study from CVS Caremark and Employee Benefit News shows how employers rely on their pharmacy benefit manager to create sustainable pharmacy solutionsprnewswire.com·3d agoE. Ohman J or Asset Management AB Decreases Holdings in CVS Health Corporation $CVSdefenseworld.net·3d agoRichard Pzena Buys LKQ Corp (LKQ) -- Shares Look 38% Undervalued on GF Valuegurufocus.com·3d agoAbbVie vs. CVS Health: Which Healthcare Stock Is a Better Buy in 2026?fool.com·3d agoHere's Why CVS Health (CVS) is a Strong Growth Stockzacks.com·3d ago

More in Medical - Healthcare Plans

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$OSCR$UNH$CLOV$HUM$CNC$CI$ELV$MOH
Voices on X · top 3 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport